Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
InCVAX by Immunophotonics for Soft Tissue Sarcoma: Likelihood of Approval
InCVAX is under clinical development by Immunophotonics and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...
InCVAX by Immunophotonics for Non-Small Cell Lung Cancer: Likelihood of Approval
InCVAX is under clinical development by Immunophotonics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
InCVAX by Immunophotonics for Solid Tumor: Likelihood of Approval
InCVAX is under clinical development by Immunophotonics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
InCVAX by Immunophotonics for Melanoma: Likelihood of Approval
InCVAX is under clinical development by Immunophotonics and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...
InCVAX by Immunophotonics for Colorectal Cancer: Likelihood of Approval
InCVAX is under clinical development by Immunophotonics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...